Menu
Recruiting NCT07283575

Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)

— Observational Metastatic Colorectal Cancer ctDNA Surveillance

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Plasma ctDNA methylation profiling.
Who it may be relevant to
Registry conditions: Metastatic Colorectal Cancer ctDNA Surveillance. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

ctDNA Methylation for Efficacy Assessment and Prognostic Prediction in Advanced Colorectal Cancer Treated With Radiotherapy Combined With or Without PD-1 Inhibitor: A Prospective Cohort Study (PROMET)

Overview

Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer receiving radiotherapy plus SOC with or without PD-1.

Detailed description

This study will enroll patients with histologically confirmed, recurrent or metastatic colorectal cancer who are eligible to receive radiotherapy in combination with standard-of-care chemotherapy, with or without PD-1 inhibitors. The study will employ ctDNA methylation detection technology to quantitatively assess ctDNA methylation levels in patient plasma samples. Blood samples will be collected at baseline and at multiple predefined timepoints during treatment. In addition, participants will undergo standard imaging surveillance (CT/MRI) every three months. The study aims to correlate ctDNA dynamics with therapeutic response, time to recurrence, and survival outcomes. Ultimately, it seeks to evaluate the potential of ctDNA monitoring for predicting treatment efficacy and prognosis, and to explore its utility in guiding clinical management for metastatic colorectal cancer.

Interventions

  • Diagnostic test Plasma ctDNA methylation profiling
    Plasma ctDNA methylation profiling was performed using an optimized single-tube multiplex mqMSP assay

Primary outcome measures

  • PFS [Time frame: up to 2 years]
Secondary outcome measures (2)
  • OS [Time frame: up to 5 year]
  • Patient-reported outcomes (quality of life) [Time frame: up to 5 year]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years old, regardless of gender;
  • Histologically confirmed, recurrent or metastatic colorectal cancer;
  • Eligible to receive radiotherapy in combination with standard-of-care chemotherapy, with or without PD-1 inhibitors.
  • With expected survival of more than 6 months;
  • The subjects (or their legal representative / Guardian) must sign the informed consent form, indicating that they understand the purpose of the study, understand the necessary procedures of the study, and are willing to participate in the study.

Exclusion criteria

  • Blood transfusion performed during operation or within 2 weeks before operation;
  • Pregnant or lactating women who have fertility and do not take adequate contraceptive measures;
  • Have a history of other malignant tumors within 5 years, except cured cervical carcinoma in situ or non melanoma skin cancer;
  • Primary brain tumor or central nerve metastasis is not under control, with obvious intracranial hypertension or neuropsychiatric symptoms;
  • Patients with the following serious or uncontrollable diseases: severe heart disease, the condition is still unstable after treatment, including myocardial infarction, congestive heart failure, unstable angina pectoris, pericardial effusion with obvious symptoms or unstable arrhythmia within 6 months before enrollment; definite neuropathy or psychosis, including dementia or seizures; severe or uncontrolled infection; active disseminated intravascular coagulation and obvious bleeding tendency;
  • Significant impairment of important organ function;
  • Other conditions in which the investigator believes that the patient should not participate in this trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Fudan University Shanghai Cancer Center — Shanghai

Identifiers

NCT: NCT07283575 · 2025-364-4513

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗